Get the Stockscreener App
0.9513
5.68%
0.0511
After Hours:
.96
0.0087
+0.91%
Elutia Inc stock is traded at $0.9513, with a volume of 62,576.
It is up +5.68% in the last 24 hours and up +38.15% over the past month.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
See More
Previous Close:
$0.9002
Open:
$0.9171
24h Volume:
62,576
Relative Volume:
0.17
Market Cap:
$40.62M
Revenue:
$24.38M
Net Income/Loss:
$-53.95M
P/E Ratio:
-0.3851
EPS:
-2.47
Net Cash Flow:
$-23.31M
1W Performance:
+0.93%
1M Performance:
+38.15%
6M Performance:
-52.20%
1Y Performance:
-66.15%
1-Day Range:
$0.9171
$1.00
1-Week Range:
$0.8507
$1.04
52-Week Range:
$0.50
$3.46
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240-247-1143
Address
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
0.9513 | 38.44M | 24.38M | -53.95M | -23.31M | -2.47 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-02-20 | Initiated | Cowen | Outperform |
| Nov-02-20 | Initiated | Piper Sandler | Overweight |
| Nov-02-20 | Initiated | Truist | Buy |
Elutia Inc Stock (ELUT) Latest News
CEO Moves: Is Elutia Inc benefiting from innovation trendsInsider Selling & Real-Time Volume Spike Alerts - baoquankhu1.vn
Options Flow: Can Elutia Inc be recession proofPrice Action & Technical Confirmation Alerts - baoquankhu1.vn
Elutia Loses US$4.6m Market Value But Insiders See Windfall Of US$60k - simplywall.st
Insider Spends US$74k Buying More Shares In Elutia - Yahoo Finance
Aug Summary: What is the Moat Score of Elutia IncStop Loss & Smart Allocation Stock Tips - baoquankhu1.vn
Trend Report: Is Elutia Inc forming a breakout patternJuly 2025 Technicals & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
ELUTIA INC (ELUT) Upgraded to Buy: Here's What You Should Know - sharewise.com
Insider Buying: Guido Neels Acquires 20,000 Shares of Elutia Inc (ELUT) - GuruFocus
Elutia Inc. director Neels buys $20,800 in shares By Investing.com - Investing.com Australia
Elutia Inc. director Neels buys $20,800 in shares - Investing.com
Elutia launches $15M securities offering - MSN
Elutia Inc: director Neels buys $31.8k in company stock By Investing.com - Investing.com South Africa
Insider Buying: Guido Neels Acquires 30,000 Shares of Elutia Inc (ELUT) - GuruFocus
Elutia Inc: director Neels buys $31.8k in company stock - Investing.com
Aug Movers: Can OPCH scale operations efficientlyMarket Performance Report & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Elutia sees Q4 net sales of $3.3M - MSN
Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance - Nasdaq
Elutia reports 16% revenue growth, advances breast reconstruction product By Investing.com - Investing.com Canada
Elutia reports 16% revenue growth, advances breast reconstruction product - Investing.com
Elutia (ELUT) Strengthens Position with Drug-Eluting Platform - GuruFocus
Elutia reports preliminary fourth quarter 2025 results, strengthened financial position, and upcoming Nxt-41X milestones - marketscreener.com
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, And Upcoming Nxt-41X Milestones - TradingView — Track All Markets
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones - The Manila Times
Press Release: Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones - 富途资讯
Elutia, Inc.Class A Common Stock (NQ: ELUT - FinancialContent
Elutia (NASDAQ:ELUT) Shares Up 4.7% – Should You Buy? - Defense World
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery - manilatimes.net
Elutia Inc. to Highlight NXT-41x Program at Inaugural Global BioInnovation Forum during JP Morgan Healthcare Conference - Quiver Quantitative
Breast reconstruction infections hit 25% of patients. A new approach emerges - Stock Titan
Why Elutia Inc. stock attracts high net worth investorsWeekly Profit Recap & Safe Entry Zone Tips - ulpravda.ru
Why Elutia Inc. stock could rally in 2025Weekly Volume Report & Weekly Momentum Stock Picks - Улправда
How Elutia Inc. stock reacts to job market dataMarket Volume Summary & Daily Risk Controlled Trade Plans - Улправда
Will Elutia Inc. stock gain from strong economy2025 Price Momentum & Daily Chart Pattern Signal Reports - ulpravda.ru
About Us | Oil & Gas JournalElutia, Inc.Class A Common Stock (Nasdaq:ELUT) Stock Quote - FinancialContent
Elutia Inc (ELUT) upgraded to buy: Here's what you should know - MSN
Gaithersburg biotech Elutia battles to keep Nasdaq listing after asset sale - The Business Journals
Where Analysts See Viviana Power Tech Limited Stock by YearEndTechnical Analysis Insights & Small Investment Growth Plans - earlytimes.in
Elutia Faces Nasdaq Noncompliance, Considers Options to Regain Listing - The Globe and Mail
Earnings Risk: Why Elutia Inc stock attracts high net worth investorsBond Market & Breakout Confirmation Alerts - moha.gov.vn
Elutia receives Nasdaq notice for non-compliance with market value and bid price rules - Investing.com India
Elutia Received Notice of Noncompliance - TradingView — Track All Markets
Elutia faces Nasdaq noncompliance, considers options to regain listing - MSN
Is Elutia Stock Built to Withstand More Downside? - Trefis
Elutia Inc Stock (ELUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):